Vancouver, British Columbia--(Newsfile Corp. - November 21, 2022) - Advanced Proteome Therapeutics Corporation (TSXV: APC) (FSE: 0E8) ("APC" or the "Company") is pleased to announce that it has appointed Mr. Cory Brandolini to the board of directors.

Mr. Brandolini has over 3 decades of experience in the capital markets and as an advisor to disruptive, high growth software companies across many verticals in the technology sector. Over the course of his career, he has helped raise hundreds of millions of dollars for public and private companies specifically in the technology sector. Mr. Brandolini's background includes two decades spent in the investment industry.

Mr. Brandolini was the Founder, CEO and Chairman of RESAAS Services Inc., an award-winning global real estate cloud platform. Under his direction, RESAAS saw its largest growth phase from a raw start up to over 400,000 subscribing realtors worldwide including the biggest brands in real estate. Mr. Brandolini took RESAAS public as one of the first true IPOs on the Canadian Securities Exchange and assisted the company in raising over $30 million in investment. Most recently, Mr. Brandolini is the Co-Founder, President and CEO of Railtown AI Technologies Inc., developers of a SAAS-delivered solution for software development teams that utilizes AI to drive optimizations and deliver insights at every stage of software development. Railtown converts CI/CD systems to full CI/CD/CM (continuous monitoring) systems - monitor, diagnose, and prioritize errors from the whole CI/CD environment on a single platform. Railtown's Continuous Machine Learning Application will empower developers to accelerate innovation while ensuring their applications reliability and increasing velocity. Additionally, he has continued to provide capital markets and M&A advisory services to technology companies, including Teleo (VoIP platform acquired by Microsoft), WISR (Artificial Intelligence Incubator), AuthenTicket (Ticket Verification Technology).

Paul Woodward, CEO of the Company, states, "We're delighted that Cory has joined the board; he's a veteran entrepreneur and investor with extensive experience in technology and capital markets. I've known Cory for many years and look forward to his contributions to APC."

ABOUT THE COMPANY:
Advanced Proteome Therapeutics Corporation, through its subsidiary, Advanced Proteome Therapeutics Inc., has invented proprietary protein conjugation technology which enables the development of superior antibody-drug conjugates through improved site-specific labeling, drug-antibody ratio control and enabling of combination payloads. The technology has compelling pre-clinical data demonstrating improved homogeneity and increased in-vivo potency relative to current state of the art linker technology. The Company believes that the technology will enable the development of safer and more potent antibody-drug conjugate therapeutics and is pursuing licensing and partnership opportunities to advance development and create shareholder value.

FOR FURTHER INFORMATION PLEASE CONTACT:
Advanced Proteome Therapeutics Corporation
Paul Woodward
President and CEO
Tel: 604 690-3797

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This news release contains forward-looking statements relating to the future operations of the Company and other statements that are not historical facts. Forward-looking statements are often identified by terms such as "will", "may", "should", "intends", "anticipates", "expects" and similar expressions. All statements other than statements of historical fact included in this release, including, without limitation, statements regarding the future plans and objectives of the Company, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company's expectations are risks detailed from time to time in the filings made by the Company with securities regulators.

Readers are cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties and other factors, many of which are beyond the control of the Company. As a result, the Company cannot guarantee that any forward-looking statement will materialize, and readers should not place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will only update or revise publicly any of the included forward-looking statements as expressly required by Canadian securities law.

To view the source version of this press release, please visit